Apoptotic Cell (AC) Uptake by Human Alveolar Macrophages (AM)

NCT01099410 | Completed

• 1 other identifier: Curtis 0015
• Study Type: observational
• Target: 17
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to compare the ability of two types of white blood cells to eat dead host cells, and how this process affects their ability to protect the body from infection. The two cell types are monocytes, a cell in the bloodstream, and alveolar macrophages, a cell in the lung that is ultimately derived from monocytes

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

macrophages, alveolar; monocytes; Receptor Protein-Tyrosine Kinases; Humans; Phagocytosis; Lung; in vitro

Outcome Measures

Primary Outcomes (1)

• macrophage uptake of apoptotic cells in vitro

  1-7 days

Secondary Outcomes (1)

• spirometric measurement of lung function

  1-30 days

Study Arms (1)

Group 1

volunteer subjects

Procedure: Fiberoptic bronchoscopy; Procedure: blood draw; Procedure: intravenous catheter

Interventions

Fiberoptic bronchoscopy PROCEDURE

which a flexible video instrument is passed via the nose or mouth, through the vocal cords and into the lungs. During the procedure, portions of the lungs will be washed ("lavaged") with a salt water solution, to collect the alveolar macrophages. This procedure involves conscious sedation, so that a driver is required on the day of the bronchoscopy. The entire procedure, including placement of an intravenous line to administer medications, local anesthetics, the bronchoscopy itself, and the recovery period, takes about 2.5-3 hours.

Group 1

blood draw PROCEDURE

Blood will be collected at the enrollment visit to test the subject to exclude disorders that would make it unsafe to perform the bronchoscopy, including severe anemia, infection, or disorders of kidney or liver function.

Group 1

intravenous catheter PROCEDURE

An intravenous catheter is placed on the day of the bronchoscopy to permit administration of sedative medications.

Also known as: IV

Group 1

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Volunteer subjects recruited from the community; may be current or ex-smokers or never-smokers, but must be healthy enough to undergo research bronchoscopy safely.

You may qualify if:

• Veteran or non-Veteran
• Able to give informed consent

You may not qualify if:

• Unstable heart disease
• Other systemic disease and unlikely to survive at least 2 years
• Mental incompetence
• Prednisone \>20 mg/day
• Participation in another interventional protocol within last 6 weeks
• Asthma
• Cystic fibrosis
• Clinically significant bronchiectasis
• Lung cancer or any cancer not in remission for at least 5 years
• Other inflammatory or fibrotic lung disease
• Use of antibiotics for a lung infection within the past 4 weeks
• Autoimmune disease, i.e., Rheumatoid arthritis, systemic lupus erythematosus, autoimmune hepatitis, Crohn's disease or other

Sponsors & Collaborators

• VA Office of Research and Development: lead

Study Sites (1)

VA Ann Arbor Healthcare System, Ann Arbor, MI

Ann Arbor, Michigan, 48105, United States

Location

Related Publications (2)

• Bourdonnay E, Zaslona Z, Penke LR, Speth JM, Schneider DJ, Przybranowski S, Swanson JA, Mancuso P, Freeman CM, Curtis JL, Peters-Golden M. Transcellular delivery of vesicular SOCS proteins from macrophages to epithelial cells blunts inflammatory signaling. J Exp Med. 2015 May 4;212(5):729-42. doi: 10.1084/jem.20141675. Epub 2015 Apr 6.

  PMID: 25847945 RESULT

• Todt JC, Freeman CM, Brown JP, Sonstein J, Ames TM, McCubbrey AL, Martinez FJ, Chensue SW, Beck JM, Curtis JL. Smoking decreases the response of human lung macrophages to double-stranded RNA by reducing TLR3 expression. Respir Res. 2013 Mar 9;14(1):33. doi: 10.1186/1465-9921-14-33.

  PMID: 23497334 RESULT

Biospecimen

Retention: NONE RETAINED

whole blood, white blood cells, serum, bronchoalveolar lavage fluid

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Study Officials

• Jeffrey L Curtis, MD

  VA Ann Arbor Healthcare System, Ann Arbor, MI

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: FED
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 30, 2010
• First Posted: April 7, 2010
• Study Start: February 1, 2010
• Primary Completion: June 1, 2015
• Study Completion: December 1, 2015
• Last Updated: January 6, 2016

Record last verified: 2016-01

Locations

US (1)